T cells are known to potentiate the bone anabolic activity of intermittent parathyroid hormone (iPTH) treatment. One of the involved mechanisms is increased T cell secretion of Wnt10b, a potent osteogenic Wnt ligand that activates Wnt signaling in stromal cells (SCs). However, additional mechanisms might play a role, including direct interactions between surface receptors expressed by T cells and SCs. Here we show that iPTH failed to promote SC proliferation and differentiation into osteoblasts (OBs) and activate Wnt signaling in SCs of mice with a global or T cell-specific deletion of the T cell costimulatory molecule CD40 ligand (CD40L). Attesting to the relevance of T cell expressed CD40L, iPTH induced a blunted increase in bone formation and failed to increase trabecular bone volume in CD40L−/− mice and mice with a T cell-specific deletion of CD40L. CD40L null mice exhibited a blunted increase in T cell production of Wnt10b and abrogated CD40 signaling in SCs in response to iPTH treatment. Therefore, expression of the T cell surface receptor CD40L enables iPTH to exert its bone anabolic activity by activating CD40 signaling in SCs and maximally stimulating T cell production of Wnt10b.
INTRODUCTION
PTH is a major regulator of calcium metabolism that exerts both anabolic and catabolic effects in bone. When injected daily, a regimen known as intermittent PTH (iPTH) treatment, the hormone markedly stimulates bone formation leading to improved bone microarchitecture and increased strength (1) . As a result, intermittent treatment with the 1-34 fragment of PTH is an FDA approved treatment modality for postmenopausal osteoporosis.
The effects of PTH on bone result from its binding to the PTH/PTH-related protein (PTHrP) receptor (PPR), expressed on bone marrow (BM) SCs, OBs, osteocytes (2) (3) (4) , T cells (5) and macrophages (6) . Among these cells osteocytes have emerged as pivotal targets of PTH because mice with conditional deletion of PPR in osteocytes exhibit a blunted response to iPTH (7, 8) while mice lacking either osteocytic PPR expression or osteocytic RANKL production are protected against the bone loss induced by continuous PTH infusion, or hyperparathyroidism secondary to low calcium diet (7) (8) (9) . iPTH stimulates bone formation by increasing the number of OBs (10) (11) (12) , a phenomenon achieved through activation of quiescent lining cells (13) , increased OB proliferation (14, 15) and differentiation (14, 16, 17) , attenuation of OB apoptosis (18) (19) (20) , and signaling in osteocytes (7, 8) . The release of TGFβ, IGF-1 and other growth factors that recruit SCs to remodeling areas initiates the expansion of the osteoblastic pool induced by iPTH (21) (22) (23) (24) . Subsequent events are driven primarily by the activation of Wnt signaling in osteoblastic cells (25) . Activation of Wnt signaling induces OB proliferation (26) and differentiation (25, 27, 28) , prevents OB apoptosis (20, 29, 30) , and augments OB production of OPG, thus blunting bone resorption (31) . iPTH activates Wnt signaling in OBs through multiple mechanisms which include Wnt ligand-independent activation of Wnt coreceptors (32) , increased production of Wnt ligands by BM cells (5, 33) , and suppression of Wnt inhibitors sclerostin (34) (35) (36) (37) and Dkk1 (38) . We have reported that T cells potentiate the bone anabolic activity of iPTH by increasing the T cell production of Wnt10b (5, 39) , a Wnt ligand that stimulates osteoblastogenesis by activating Wnt signaling in SCs and OBs. As a result, the bone anabolic activity of iPTH is markedly reduced in T cell-deficient mice and in mice with a specific disruption of Wnt10b production by T cells (5) .
Additional interactions between T cells and SCs may contribute to the anabolic activity of
iPTH. An important mediator of T cell-SC interaction is the T cell costimulatory ligand CD40L 40) . This surface molecule, also known as CD154, exerts its effects by binding to CD40 (41) and several integrins (42) (43) (44) (45) . CD40 is expressed on antigen presenting cells (46) , SCs and OBs (47) . The CD40/CD40L system is crucial for T cell activation and several functions of the immune system. It promotes macrophage activation and differentiation, antibody isotype switching, and the adequate organization of immunologic memory in B cells (48) . Additionally, binding to the integrins α IIb β 3 (42, 43) , Mac-1 (44) , and α 5 β 1 , which are widely expressed in the BM, is known to account for inflammatory effects of CD40L (45) .
Studies in humans and mice have demonstrated that the CD40L/CD40 system is required to maintain normal bone modeling and remodeling (49, 50) . CD40L has been linked to post natal skeletal maturation because children affected by X-linked hyper-IgM syndrome, a condition in which CD40L production is impaired due to a mutation of the CD40L gene, have low bone density (49) . Two mechanisms have been identified to link the CD40L/CD40 system to skeletal maturation. Firstly, activation of CD40 signaling in B cells by T cell expressed CD40L promotes production of the anti-osteoclastogenic factor OPG by B-cells (50) , thereby decreasing bone resorption. In addition, activation of CD40 signaling in SCs by T cell expressed CD40L provides proliferative and survival cues to SCs in vitro and in vivo (47, 51) . Attesting to its relevance, CD40L has been implicated in the mechanism of action of estrogen in bone (52) and the expansion of hemopoietic stem cells induced by estrogen deficiency (53) . CD40L is also required for continuous PTH treatment, a model of primary hyperparathyroidism, to expand SCs and their osteoblastic progeny and increase the osteoclastogenic activity of SCs (51, 52) .
These studies demonstrate that a cross-talk between T cells and SCs mediated by CD40L plays a pivotal role in maintaining a physiologic pool of osteoblastic cells in baseline and stimulated conditions. Therefore, it is reasonable to hypothesize that the trophic activity exerted by CD40L on SCs may be required for iPTH to exert its full activity in bone. This study was designed to investigate the contribution of CD40L to the bone anabolic activity of iPTH treatment. We report that T cell expressed CD40L potentiates the bone anabolic activity of iPTH by promoting SC expansion and lifespan.
RESULTS
To investigate whether CD40L contributes to the bone anabolic activity of iPTH, WT and CD40L−/− mice were injected subcutaneously once a day for 4 weeks starting at the age of 12 weeks with vehicle or hPTH 1-34 at 80 μg/kg/day, a treatment modality referred to hereafter as iPTH. To assess the differential effects of iPTH on cortical and trabecular bone, micro-computed tomography (μCT) was utilized to analyze femurs harvested at sacrifice. iPTH induced a large gain in trabecular bone volume (BV/TV) in WT mice whereas it had no significant effect in CD40L−/− mice ( fig. 1a ). Parameters of trabecular structure were also differentially affected by iPTH in WT and CD40L−/− mice. In fact, iPTH increased trabecular thickness (Tb.Th) and trabecular number (Tb.N) in WT but not in CD40L−/− mice ( fig. 1b -c). IPTH did not affect trabecular space (Tb.Sp) in either group of mice ( fig.  1d ). While T cells potentiate trabecular anabolism, iPTH induces cortical bone accretion via T cell independent mechanisms (5) . Accordingly, analysis of femoral cortical bone revealed that iPTH equally increased cortical volume (Ct. In agreement with previous reports (51) , analysis of femoral cancellous bone by histomorphometry revealed that two indices of bone resorption, the number of OCs per bone surface (N.Oc/BS) and the percentage of surfaces covered by OCs (Oc.S/BS) were higher in CD40L−/− mice as compared to WT mice ( fig. 2a,b ). This analysis further disclosed that iPTH treatment induced a greater increase in N.Oc/BS and Oc.S/BS in WT mice as compared to CD40L−/− mice. Moreover, analysis of dynamic indices of bone formation revealed that iPTH induced a greater increase in mineral apposition rate (MAR) and bone formation rate (BFR) in WT than in CD40L−/− mice ( fig. 2c ). These findings demonstrate that silencing of CD40L blunts the capacity of iPTH to stimulate bone resorption and bone formation. This interpretation was confirmed by measurements of serum levels of Cterminal telopeptide of collagen (CTX), a marker of bone resorption, and procollagen type 1 N-terminal propeptide (P1NP), a marker of bone formation. In fact, treatment with iPTH increased the levels of CTX and P1NP in WT but not in CD40L−/− mice ( fig. 2d ,e).
To determine whether CD40L is required for iPTH to regulate RANKL expression, BM was harvested from WT and CD40L−/− mice after 4 weeks of treatment with vehicle or iPTH, cultured for 1 week and utilized to purify SCs. Analysis of RANKL mRNA levels in SCs revealed that treatment with iPTH increased the levels of RANKL mRNA in WT but not in CD40L−/− mice ( fig. 2f ). We also assessed the effects of iPTH on the mRNA levels of OPG. However, since CD40L induces OPG production by B cells and SCs, OPG mRNA was measured in whole BM samples from WT and CD40L−/− mice. These experiments revealed that iPTH decreased OPG mRNA expression in BM cells from WT but not CD40L −/− mice ( fig. 2g ).
A pivotal mechanism by which iPTH stimulates bone formation and increases bone volume is by upregulating the production of Wnt10b by T cells (5) . We thus investigated whether CD40L is required for iPTH to increase T cell production of Wnt10b. To achieve this goal WT mice and CD40L−/− mice were treated with vehicle or iPTH for four weeks. Analysis of whole BM and BM T cells harvested at sacrifice revealed that the BM and T cell levels of Wnt10b mRNA were more potently increased by iPTH in WT than in CD40L−/− mice ( fig.  3a ,b), indicating that the expression of CD40L is required for iPTH to fully upregulate T cell Wnt10b expression.
CD40L activates CD40 signaling in osteoblastic cells (47) . To assess the effects of iPTH on CD40 signaling we measured non-canonical NF-kB activation and the relative expression of genes specifically upregulated by CD40 signaling, namely Pim-1 and Survivin (54, 55) . We found iPTH increases the processing of p100 into p52 in WT SCs ( fig. 3c ). In addition, iPTH induced a 16-fold increase in Pim-1 and a 3-fold increase in Survivin in SCs from WT mice ( fig. 3d,e ). By contrast, iPTH had no effect in SCs from CD40L−/− mice.
To investigate the role of CD40L on SC differentiation, BM was harvested at the end of the treatment period and cultured for 1 week to assess the formation of alkaline phosphatase (ALP) positive colony forming unit-fibroblast (CFU-F), herein defined CFU-ALP, an index of SC commitment to the osteoblastic lineage. iPTH increased CFU-ALP formation by ~2fold in the BM from WT mice and CD40L null mice ( fig. 4a ), indicating that iPTH increases the number of SCs with osteogenic potential through CD40L independent mechanisms. To determine whether CD40L is required for iPTH-induced SC proliferation and survival, BM from WT and CD40L−/− mice harvested after treatment with vehicle or iPTH was cultured for 1 week and SCs were purified and used to determine their rate of proliferation and apoptosis. This experiment revealed that iPTH increased the proliferation of SCs from control mice, whereas it did not affect the proliferation of SCs from CD40L−/− mice ( fig.  4b ). Moreover, iPTH decreased the rate of SC apoptosis in control mice but not in CD40L−/ − mice ( fig. 4c ). iPTH increased alkaline phosphatase (ALP) mRNA levels in SCs from WT and CD40L−/− mice. However, the effect of iPTH was more potent in WT than in CD40L−/ − SCs ( fig. 4d ).
Analysis of the expression levels of osteoblastic genes that correlate with SC differentiation into OBs revealed that iPTH increased the expression of bone sialoprotein (BSP), type 1 collagen (CoL1), osteocalcin (Ocn), osterix (Osx), and Runx2 mRNAs by ~ 2-3 fold in SCs from WT mice ( fig. 4e ). In contrast, iPTH had no effect on the expression of OB-related genes in SCs from CD40L null mice, thus demonstrating that CD40L is required for T cells to expand the osteoblastic pool in iPTH treated mice.
Since iPTH induces canonical Wnt activation in osteoblastic cells we sought to investigate whether iPTH activates Wnt signaling in SCs through CD40L. Therefore, we harvested SCs from mice treated with vehicle or iPTH for 4 weeks and then analyzed the mRNA expression of genes specifically upregulated by Wnt signaling. The analyzed genes were: aryl-hydrocarbon receptor (Ahr), axin2, cysteine rich protein 61 (Cyr61), naked cuticle 2 homolog (Nkd2), transgelin (tagln), transforming growth factor β3 (TGFβ3), thrombospondin 1 (Thbs1), Twist gene homolog 1 (Twist1) and Wnt1 inducible signaling pathway protein 1 (Wisp1). These genes were chosen because they are sensitive markers of Wnt activation (56) . Analysis of purified SCs revealed that the levels of mRNA for the 9 tested genes were all increased by iPTH in SCs from WT mice ( fig. 4f ). By contrast, iPTH did not significantly increase the expression of Wnt dependent genes in SCs from CD40L−/ − mice.
To investigate the specific role of T cell expressed CD40L in the anabolic activity of iPTH, additional experiments were carried out using TCRβ−/− mice, a strain completely devoid of αβ T cells, and TCRβ−/− mice subjected to adoptive transfer of T cells harvested from WT or CD40L−/− mice 2 weeks before the start of treatment with vehicle or iPTH. Flow cytometric analysis of splenocytes harvested at death from mice subjected to adoptive transfer of T cells confirmed the engraftment and the expansion of adoptively transferred T cells (supplemental figure 1 ). Measurements of femoral BV/TV by μCT at the end of a 4 week long treatment period revealed ( fig. 5a ) that iPTH increased BV/TV in TCRβ−/− animals reconstituted with WT T cells, whereas it had no effect in either T-cell-deficient mice or TCRβ−/− mice reconstituted with CD40L−/− T cells. Parameters of trabecular structure were also differentially affected by iPTH in mice lacking T cells or T cell expression of CD40L, as compared to control mice with WT T cells. In fact, Tb.Th, Tb.N, and Tb.Sp were more potently improved by iPTH in TCRβ−/− animals reconstituted with WT T cells, as compared to T-cell-deficient mice and TCRβ−/− mice reconstituted with CD40L−/− T cells. ( fig. 5b-d) . As expected, we found that iPTH increased Ct.Vo ( fig. 5e ) and Ct.Th ( fig. 5f ) in all groups of mice. Measurements of biochemical indices of bone turnover revealed that treatment with iPTH increased CTX levels in TCRβ−/− animals reconstituted with WT T cells, whereas it had no effect in both T-cell-deficient mice and TCRβ−/− mice reconstituted with CD40L−/− T cells ( fig. 5g ). Moreover, iPTH induced a greater increase in serum P1NP levels in TCRβ−/− animals reconstituted with WT T cells than in T cell deficient TCRβ−/− mice or TCRβ−/− mice reconstituted with CD40L−/− T cells ( fig. 5h ).
Additional experiments revealed that iPTH increased SC proliferation ( fig. 6a ), blunted SC apoptosis ( fig. 6b ) and increased the SC expression of osteoblastic genes that correlate with SC differentiation into OBs (bone sialoprotein, type 1 collagen, osteocalcin, osterix, and Runx2) ( fig. 6c ) in TCRβ−/− animals reconstituted with WT T cells, whereas it had no effect in either T-cell-deficient mice or TCRβ−/− mice reconstituted with CD40L−/− T cells. Moreover, iPTH increased the expression of the Wnt dependent genes Ahr, Axin2, Cyr61, Nkd2, Tagln, TGFβ3, Thbs1, Twist1 and Wisp1 in TCRβ−/− animals reconstituted with WT T cells but not in TCRβ−/− mice and TCRβ−/− mice reconstituted with CD40L−/− T cells ( fig. 6d ). These findings demonstrate that CD40L signaling is required for T cells to regulate SC function.
DISCUSSION
We report that in vivo silencing of the T cell costimulatory molecule CD40L blunts the effects of iPTH on SC proliferation, differentiation and lifespan, and completely blocks the anabolic activity of iPTH on trabecular bone. Deletion of CD40L decreases the osteoblastogenic activity of iPTH by preventing the activation of Wnt signaling. As CD40L is expressed not only in T cells but also in platelets, T cell reconstitution studies were carried out to assess the specific contribution of T cell expressed CD40L. The results of these studies demonstrate that T cells are the source of CD40L required for iPTH to exert its full anabolic activity. The contribution of T cells and CD40L to the anabolic activity of iPTH is summarized in Fig. 7 .
Our data demonstrate that the blunted capacity of iPTH to increase trabecular bone formation in CD40L−/− mice resulted from alterations in the stimulatory effects of iPTH on SCs. Specifically, we found CD40L to be required for iPTH to increase proliferation and life span of SCs and their differentiation into OBs. iPTH stimulates osteoblastogenesis and OB life span by activating Wnt signaling. Attesting to the relevance of CD40L, iPTH fails to activate Wnt signaling in SCs from mice with a global or T cell-specific silencing of CD40L. The finding that iPTH increases non-canonical NFKB activation and the expression of Pim-1 and Survivin mRNA in SCs demonstrates that iPTH induces CD40 signaling in SCs. Therefore, activation of CD40 signaling is likely to account for the direct effects of CD40L in SCs.
Differences between control and CD40L−/− mice with respect to iPTH-induced SC proliferation and differentiation were demonstrated using SCs purified from BM cells cultured for 1 week. The long-term persistence in vitro of the effects of CD40L silencing in vivo suggests that CD40L signaling regulates the selection and differentiation of SCs in vivo, leading to the emergence of highly osteoblastogenic SC lineages and/or lineages of SCs that are highly responsive to the direct effects of iPTH. A similar paradigm has been described in our earlier studies on the effects of iPTH in T cell-deficient mice (5) and in ovariectomized mice, a model in which estrogen withdrawal leads to the formation of SCs that exhibit increased osteoclastogenic activity, which persists in vitro for 4 weeks (52, 57) .
The bone building activity of iPTH is due to a potent stimulation of bone formation mitigated, in part, by a concomitant stimulation of bone resorption. While activation of Wnt signaling in osteoblastic cells by iPTH accounts for the increase in bone formation, the increase in bone resorption induced by iPTH is driven by increased production of RANKL by osteocytes (9) , their osteoblastic precursors (58) , and T cells (5) . Measurements of indices of bone turnover by histomorphometry and biochemical assays revealed that silencing of CD40L blocked the increase in bone formation and resorption induced by iPTH. We have previously reported that silencing of CD40L abrogates the capacity of continuous PTH treatment to increase M-CSF production and the RANKL/OPG ratio in SCs and to stimulate their osteoclastogenic activity (51) . Thus, it is likely that activation of CD40 signaling is required for iPTH to regulate SC osteoclastogenic activity and their production of osteoclastogenic factors.
We have previously shown that T cells potentiate the bone anabolic activity of iPTH by increasing the T cell production of Wnt10b (5, 39) , The results of the current investigation show that T cell expression of CD40L is also required for iPTH to exert its bone anabolic activity. Silencing of T cell expression of either Wnt10b (5, 39) or CD40L blocks Wnt activation in SCs and the increase in osteoblastogenesis and trabecular bone volume induced by iPTH. These data point to a pivotal mechanistic role of T cell produced Wnt10b and CD40L as mediators of the anabolic effect of iPTH.
Deletion of CD40L blunts, but does not completely block, the upregulation of Wnt10b induced by iPTH. This finding is consistent with the notion that Wnt10b is primarily produced by activated T cells, (59) as CD40L is a T cell surface receptor required for sustaining T cell activation (52) . However, iPTH upregulates Wnt10b production only partially through CD40L, as direct targeting of T cells by PTH and the resulting ligand activation of PPR receptor expressed in T cells (39) are required for full upregulation of Wnt10b production.
Since silencing of CD40L completely blocks the anabolic activity of iPTH while decreasing T cell Wnt10b mRNA expression by ~ 25%, it is likely that Wnt10b mediates only a part of the effects of CD40L. Therefore, Wnt10b and CD40L regulate the effects of iPTH in bone by acting mostly as independent T cell signals.
Our findings are not in contrast with the growing evidence that repression of the SOST gene, which encodes for the Wnt inhibitor sclerostin, is a key mechanism of iPTH induced Wnt activation (37, 60) . An earlier report from our laboratory established that T cell mediated mechanisms accounts for the sclerostin-independent activity of iPTH (61) .
That study demonstrated a requirement for T cell production of Wnt10b (61) . The current investigation suggest that T cells need to express CD40L and produce Wnt10b in order to complement the effects of sclerostin inhibition induced by iPTH.
Importantly, the contribution of CD40L to the anabolic activity of iPTH was limited to the trabecular compartment of the skeleton. This finding is in agreement with earlier reports from our laboratory demonstrating that T cells specifically potentiate the anabolic activity of iPTH in trabecular but not cortical bone (5, 39) . The mechanism responsible for the T cell and CD40L independent activity of iPTH in cortical bone remains to be determined. T cells account for ~ 5 % of the mononuclear cells of the BM (62, 63) . T cells are highly mobile cells distributed among the BM stroma and parenchyma (63, 64) and some T cell lineages reside preferentially on the endosteal surfaces of bone (65) . Therefore T cells can regulate osteoblastic cells in the trabecular compartment of the skeleton via cell surface receptors such as CD40L, and by releasing cytokines and Wnt ligands (66) . T cells also contribute to the regulation of the hemopoietic stem cell niche (53, 67) and hematopoiesis (68) . By contrast T cells do not reside on the periosteal surface of the bone and have limited capacity to communicate with osteocytes, which are critical targets of iPTH in cortical bone (7) (8) (9) . Therefore the fact that T cells do not mediate the effects of iPTH in cortical bone is likely to be related to the lack of direct signaling between T cells and osteocytes. While most of the anabolic effect of iPTH in cortical bone is due to suppression of osteocytic sclerostin production (7, 8, 61) , it is possible that increased production of Wnt10b or other Wnt ligands by osteocytes may contribute to the T cell and CD40L-independent effects of iPTH on cortical bone.
In summary, the present investigation demonstrates that one mechanism by which iPTH activates osteoblastogenesis involves the T cell costimulatory receptor CD40L. Understanding the cross-talk between T cells and SCs may yield novel therapeutic strategies for potentiating the anabolic activity of iPTH.
METHODS

Animals
All animal procedures were approved by the Institutional Animal Care and Use Committee of Emory University. Female C57BL6/J, C57BL6/J TCRβ−/− and C57BL6/J CD40L−/− mice were purchased from Jackson Laboratories (Bar Harbor, ME). All mice were maintained under specific pathogen free conditions and fed sterilized food and autoclaved water ad libitum.
Intermittent Administration of PTH
Human PTH (1-34) (Bachem California, Inc., Torrance, CA) or vehicle was injected at doses of 80 μg/kg/day subcutaneously for 4 weeks starting with 12-week-old mice. Femoral bone density was measured in vivo by DEXA at baseline. Mice were assigned to the vehicle or the iPTH group based on their baseline bone density so as that the vehicle and the iPTH groups had similar baseline mean bone density values.
injections to allow the engraftment and the peripheral expansion of the transferred T cells. Successful T cell engraftment was confirmed by flow cytometry of the spleens of the recipient mice harvested at sacrifice.
SC purification
BM was collected from long bones by centrifugation and cultured for 7 days in α-MEM medium containing 10% FBS, 100mg/ml of penicillin, and 100 IU/ml of streptomycin, to allow the proliferation of SCs. After discarding non-adherent cells, adherent macrophages were eliminated by positive immunoselection by MACS Microbeads (Miltenyi Biotech, Auburn, CA) coupled to anti-CD11c antibody. This marker is expressed on non-adherent dendritic cells and adherent monocytes and macrophages. The remaining adherent cells were defined as SCs as they express ALP, type-I collagen, Runx2, and have the capacity to form mineralization nodules when further cultured under mineralizing conditions.
Immunoblots SC extracts were prepared as described in Bio-Rad (Hercules, CA) general protocol for Western blotting and analyzed by SDS-PAGE. The blots were immunoblotted with NF-kB2 p100/p52 (Cell Signaling Technology, Inc., Danvers, MA) and GAPDH (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) specific antibodies.
Flow cytometry
To confirm the outcome of the T cell transfer studies spleen cells were stained with monoclonal antibodies against the following molecules: CD3 (145-2C11), CD4 (GK1.5) and CD8 (53-6.7) from Biolegend (San Diego, CA). Surface stained cells were measured by an Accuri C6 flow cytometer (BD Biosciences) or a FACS LSRII (Becton Dickinson, San Jose, CA), and analyzed using C6 software or FlowJo software (TreeStar, Ashland, OR).
μCT Measurements μCT scanning and analysis was performed as reported previously (5, 69) reported. When the statistical interaction was statistically significant or suggestive of an important interaction then t-tests were used to compare the differences between the treatment means for each animal strain, applying the Bonferroni correction for multiple comparisons. 
